Patent · US Active

Chimeric proteins for targeting dsRNA

US11230580B2 · kind B2 · utility

0Cited by

2References

20Claims

0Family size

Assignee

TARGIMMUNE THERAPEUTICS AG · CH

Inventors

Alexander Levitzki · Melrose, US
Yael Langut · Haifa, IL
Nufar Edinger · Kiryat Malachi, IL

Key dates

Filing date	Mar 8, 2018
Grant date	Jan 25, 2022
Priority date	—
Expiry date	Mar 29, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2320/32
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Described herein are recombinant chimeric proteins comprising a double stranded RNA (dsRNA) binding domain and a cancer-cell targeting domain for targeting of dsRNA to cancer cells. Methods of use of the described chimeric proteins are also provided herein.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.